Results of LSA2‐L2 therapy in 26 children with non‐hodgkin's lymphoma von Pichler, Eva, Jürgenssen, Olaf‐Arne, Radaszkiewicz, Thaddäus, Reinartz, Gisela, Mutz, Ingomar, Urban, Christian, Krepler, Paul, Schmidmeier, Waltraud, Becker, Hans, Kundi, Michael

Volltext

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study von Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof

Volltext

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial von Eggermont, Alexander M M, Blank, Christian U, Mandala, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline

Volltext

Oncogenic BRAF-Mediated Melanoma Cell Invasion von Lu, Hezhe, Liu, Shujing, Zhang, Gao, Kwong, Lawrence N., Zhu, Yueyao, Miller, John P., Hu, Yi, Zhong, Wenqun, Zeng, Jingwen, Wu, Lawrence, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Xu, Wei, Karakousis, Giorgos C., Schuchter, Lynn M., Field, Jeffery, Zhang, Paul J., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei

Volltext

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma von Eggermont, Alexander M M, Blank, Christian U, Mandala, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhail, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus Jm, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, Lupinacci, Robert, Krepler, Clemens, Ibrahim, Nageatte, Kicinski, Michal, Marreaud, Sandrine, van Akkooi, Alexander C, Suciu, Stefan, Robert, Caroline

Volltext

Abstract 1682: Non-V600 BRAF mutants in melanoma: Multiple MAPK mutations and distinctive RNA expression von Kiernan, Elizabeth, Bastian, Paul, Dorfman, Liza, Anastopoulos, Ioannis N., Wubbenhorst, Brad, Krepler, Clemens, Rebecca, Vito, Herlyn, Meenhard, Nathanson, Katherine

Volltext

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high... von Eggermont, Alexander MM, Meshcheryakov, Andrey, Atkinson, Victoria, Blank, Christian U., Mandala, Mario, Long, Georgina V., Barrow, Catherine, Di Giacomo, Anna Maria, Fisher, Rosalie, Sandhu, Shahneen, Kudchadkar, Ragini, Ortiz Romero, Pablo Luis, Svane, Inge Marie, Larkin, James, Puig, Susana, Hersey, Peter, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Mohr, Peter, Hernberg, Micaela, Chiarion-Sileni, Vanna, Strother, Matthew, Hauschild, Axel, Yamazaki, Naoya, van Akkooi, Alexander CJ, Lorigan, Paul, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline

Volltext

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma von Long, Georgina V., Schachter, Jacob, Arance, Ana, Grob, Jean-Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S., Ribas, Antoni, McNeil, Catriona M., Lotem, Michal, Larkin, James M. G., Lorigan, Paul, Neyns, Bart, Blank, Christian U., Petrella, Teresa M., Hamid, Omid, Jensen, Erin, Krepler, Clemens, Diede, Scott J., Robert, Caroline

Volltext

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma:Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial von Eggermont, Alexander M.M, Blank, Christian U, Mandala, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J.M, Grob, Jean Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C.J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline

Volltext

Reply to E. Hindié von Eggermont, Alexander M M, Blank, Christian U, Mandala, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline

Volltext

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma von Robert, Caroline, Schachter, Jacob, Long, Georgina V., Arance, Ana, Grob, Jean-Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S., McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U., Hamid, Omid, Petrella, Teresa M., Anderson, James, Krepler, Clemens, Diede, Scott J., Ribas, Antoni

Volltext

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006 von Long, Georgina V., Schachter, Jacob, Ribas, Antoni, Arance, Ana M., Grob, Jean-Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S., McNeil, Catriona M., Lotem, Michal, Larkin, James M. G., Lorigan, Paul, Neyns, Bart, Blank, Christian U., Petrella, Teresa M., Hamid, Omid, Anderson, James, Krepler, Clemens, Ibrahim, Nageatte, Robert, Caroline

Volltext

Altered bone matrix mineralization in a patient with Rett syndrome von Hofstaetter, Jochen G, Roetzer, Katharina M, Krepler, Petra, Nawrot-Wawrzyniak, Kamilla, Schwarzbraun, Thomas, Klaushofer, Klaus, Roschger, Paul

Volltext